News
We send the latest information from SMC Laboratories.
SMC attend Digital partnering events!
We are pleased to announce that SMC Laboratories will be virtually attending the following digital events in M…
Introduction of NASH model with high clinical correlation
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Around t…
Hyogo Medical University publishes HBV study featuring our histopathological analysis of hepatic steatosis
SMC is proud to announce that Hyogo Medical University (JPN) has published a study featuring histopathological…
Study published in Cell Metabolism on the efficacy of MGAT2 inhibitor in STAM™
SMC is proud to announce that Bristol-Myers Squibb (NJ) has published the results of their study using our pre…
March 9th is World Kidney Day!
Today, in celebration of World Kidney Day, we would like to share with you a little bit about the campaigns hi…
Introduction of Bile duct ligation (BDL)-induced primary biliary cirrhosis model
Today, we would like to introduce our bile duct ligation (BDL)-induced primary biliary cirrhosis disease model…
Introduction of bleomycin-induced SSc-ILD model
Today, we would like to introduce a more clinically correlative model in which skin and lung fibrosis develop …
Announcement of webinar 【Creating high quality non-clinical study designs based on clinical trials】
Today we are excited to invite you to join our Online Linkedin Webinar that will be taking place on February 1…
Introduction of positive control drug for kidney fibrosis mouse model
Today, we would like to introduce an established positive control – an ALK5 inhibitor – for our Un…
Introduction of our experiences in histopathological analyses for IPF
Today, we present some new histopathological data from our bleomycin-induced pulmonary fibrosis model, which i…